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Abstract
Infection by protozoan parasites of the genus Leishmania results in the development of 
leishmaniasis, an increasingly prevalent group of diseases affecting over 12 million people 
worldwide. Leishmaniasis can have very different outcomes ranging from cutaneous lesions, 
mucosal lesions to visceralization depending on the species of the infecting parasite and on the 
immune response developed by the host. As an obligate intracellular parasite, residing within 
macrophages, Leishmania evolved in strict contact with the host immune system, developing 
different mechanisms to evade or modulate the immune response. Various types of immune 
responses are observed during different Leishmania spp. infections, resulting in parasite clearance 
but also contributing to the pathogenesis, thus increasing the complexity of the course of the 
disease. Interestingly, depending on the type of leishmaniasis developed, opposite treatment 
strategies, which either boost or inhibit the inflammatory response, have shown efficacy. In this 
review, we summarize the contribution of different immune cell types to the development of the anti-
leishmanial immune response and the parasite strategies to evade and modulate host immunity. 
Further, we discuss the involvement of co-infecting pathogens in the determination of the outcome 
of leishmaniasis and on the effectiveness of treatment and the implication of the immune response 
for treatment and vaccine development.
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Introduction
Infection with the protozoan parasite Leishmania can lead to 
the development of leishmaniasis, a prominent but neglected 
disease affecting over 12 million people worldwide, with an 
increasing geographical extension, limited treatment options 
and still no human vaccine (1, 2). Depending principally on 
the species of the infecting parasite, leishmaniasis can have 
a wide spectrum of manifestations (2). Cutaneous leishman-
iasis (CL) is most frequently displayed as ulcerating skin 
lesions at the site of the sand fly bite, and caused by species 
such as L. major, L. braziliensis or L. guyanensis (2, 3).
CL can evolve into mucocutaneous cutaneous leishman-
iasis (MCL) or disseminated cutaneous leishmaniasis (DCL), 
two more severe forms of the disease characterized by para-
site migration to secondary sites and the formation of meta-
static lesions (4, 5). Interestingly, these secondary lesions 
often present very low parasite numbers, but concomitant 
exaggerated inflammation provokes tissue destruction. This 
dissemination and re-activation of the infection at second-
ary sites can occur years after the primary infection and are 
observed with species such as L. braziliensis, L. guyanensis 
and L. aethiopica. Despite being less frequent than CL, vis-
ceral leishmaniasis (VL), caused by L. donovani and L. infan-
tum, is the most dangerous manifestation and is characterized 
by parasite dissemination to the liver and spleen that can be 
fatal if left untreated.
Aside from the species of the infecting parasite, the out-
come of leishmaniasis is mainly determined by the host 
immune response and several immune-related genetic pol-
ymorphisms have been associated with the severity of the 
disease. Leishmania being obligate intracellular parasites, 
after the transmission to humans by a sand fly bite, they 
need to rapidly locate their host cells. In the mammalian host, 
Leishmania reside mainly in long-lived resident macrophages 
where they differentiate from promastigotes to amastigotes 
and then survive in the hostile, acidic and higher temperature 
environment of a phago-lysosome-like organelle. To establish 
the infection, some (but not all) Leishmania species require 
the recruitment of inflammatory monocytes, macrophages 
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and neutrophils at the infection site. Once inside its host cell, 
Leishmania hide from the immune system to survive. Thus, 
Leishmania had to develop different strategies to shape the 
immune response from its very beginning, affecting both 
innate and adaptive immunity to promote its own survival.
Considering the abundance of excellent recent reviews on 
leishmaniasis, we will focus our review on some of the actual 
knowledge of innate and adaptive immune responses to 
Leishmania and parasite evasion techniques, then address 
the effect of co-infections on leishmaniasis and finally analyze 
the implications for treatment and vaccine development.
Innate immunity to Leishmania
The first hours after the infection are crucial for obligate intra-
cellular Leishmania parasites to rapidly localize phagocytes 
to colonize its host. At this initial stage, Leishmania benefit 
from pro-inflammatory properties of the sand fly saliva that 
plays an essential role in phagocyte chemo-attraction, being 
thus an important determinant of infection outcome (6). The 
early phases of Leishmania infection are also affected by 
the dual role of complement, as complement-mediated lysis 
eliminates parasites whereas opsonization promotes para-
site up-take by phagocytes, thus favoring the infection. The 
Leishmania lipophosphoglycan (LPG) coat protects the para-
site from complement-mediated lysis and at the same time 
induces complement activation, thus promoting parasite 
phagocytosis (7). Moreover, leishmanial LPG delays the for-
mation of phago-lysosomes and allows Leishmania parasites 
to differentiate into its intracellular form, the amastigote (8).
Leishmania and macrophages
The long-lasting Leishmania infection is established within 
macrophages (phagocytic cells usually specialized in the 
elimination of intracellular pathogens) confining the parasite 
in a phago-lysosome organelle filled with lytic enzymes and 
low pH. In the first hours of the infection, the most effective 
anti-Leishmania response of the macrophages is the pro-
duction of reactive oxygen species (ROS) and reactive nitro-
gen species (RNS) (9, 10), a tightly regulated process that 
aims to kill any invading pathogen without damaging the host 
cell. This process is in part activated by phagocytosis and 
involves several enzymes. The two major producers of react-
ive species in macrophages are NADPH oxidase 2 (NOX2) 
and inducible nitric oxide synthase (iNOS), which produce 
superoxide (O2
–) and nitric oxide (NO
.
), respectively (11, 12).
Evidently, Leishmania parasites have developed various 
strategies to interfere with this process (13) (see Fig. 1), such 
as the LPG shield that protects parasites from ROS and RNS 
and subsequently delays the assembly of NOX2 at the sur-
face of the phago-lysosome in the phagocytic cup, thus sus-
pending the production of O2
– (14). This process is further 
exploited by amastigotes, because of a thick layer of LPG 
(15). Further, Leishmania parasites can secrete or induce 
macrophages to produce arginase, which competes with 
iNOS for arginine and produces essential nutrients for the 
parasites such as l-ornithine for the synthesis of polyamines 
and urea, and at the same time diminishes the production of 
parasitotoxic NO
.
 (16). Oxidative stress could also be further 
inhibited by the leishmanial metalloprotease gp63, which 
interferes with macrophage signaling pathways leading to 
NOX2 and iNOS induction (17).
Interestingly, L. braziliensis and L. amazonensis have been 
shown to increase macrophage superoxide dismutase (SOD) 
expression, through the induction of type I  interferons, thus 
favoring parasite survival (18), possibly acting in concert 
with various leishmanial antioxidant analogues present in the 
parasite (19–21).
In conclusion, Leishmania parasites actively master the 
oxidative stress from their initial entry to their survival in the 
macrophage.
Leishmania and neutrophils
Beside macrophages, Leishmania parasites can also be 
trapped by neutrophils that are rapidly recruited to the infec-
tion site, where they produce ‘neutrophil extracellular traps’ 
(NETs). These are a network of extracellular fibrils composed 
of DNA associated with antimicrobial proteins such as elas-
tase, histones and toxic granules.
Despite usually being very short-lived immune cells, the 
neutrophil life-span highly expands during inflammation. 
However, the impact of neutrophils on leishmaniasis outcome 
is likely species-specific (22). In fact, while L.  amazonen-
sis parasites are efficiently killed by NETs, L. donovani and 
L.  infantum are resistant and may even benefit from NETs 
formation (23). Moreover, the rapid recruitment of neutrophils 
Fig. 1. Mechanisms of Leishmania interference with the macrophage 
oxidative stress response. Leishmania parasites have developed 
different strategies to interfere with the macrophage oxidative 
stress response. (1) Early after phagocytosis, the leishmanial LPG 
coat inhibits the assembly of the NOX2 complex at the phagosome 
membrane, thus blocking superoxide production (O2
–). (2) Leishmania 
secrete a series of peroxidases which detoxify parasitotoxic 
peroxynitrite (ONOO–). In addition, Leishmania parasites can secrete 
arginase (3), which promotes the conversion of arginine into urea and 
ornithine used for parasite metabolism, and secrete SOD homologues 
(4), which increase the detoxification of parasitotoxic superoxide. 
(5) Additionally, stimulation of TLR2 or the type I  interferon receptor 
(IFNAR) during Leishmania infection induces macrophages to 
up-regulate SOD expression. (6) NLRP3 inflammasome activation was 
shown to promote the production of ROS and RNS; Leishmania inhibits 
inflammasome activation via the induction of the deubiquitinating 
protein A20, which inhibits IL-1β maturation.
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during L. mexicana infection contributes to disease progres-
sion and chronicity (24). Further, an increased recruitment of 
neutrophils was observed in mice co-infected with L. major 
and lymphocytic choriomeningitis virus (LCMV), which devel-
oped more severe lesions compared to controls infected with 
just L. major (25). The molecular signatures or mechanisms 
underlying these differences in the relation between neutro-
phils and different Leishmania species are not yet known and 
would deserve thorough investigations.
Leishmania and inflammatory monocytes
Not only resident macrophages and neutrophils, but also in-
flammatory monocytes, recruited via platelet activation very 
early at the infection site, can be infected by Leishmania par-
asites, as was shown for L. major (26). In general, recruitment 
of inflammatory monocytes correlates with increased resist-
ance to L.  major infection (26). Inflammatory monocyte re-
cruitment depends on chemokine (C-C motif) ligand 2 (CCL2/
MCP-1), which is produced by cells at the infection site upon 
activation via platelet-derived growth factor (26). The import-
ance of CCL2 and recruitment of inflammatory monocytes at 
the site of infection was investigated in C-C chemokine re-
ceptor type 2 (CCR2)–/– mice infected with L.  major, where 
a non-healing phenotype was observed in a mouse strain 
usually controlling Leishmania infection. Thus, recruitment of 
inflammatory monocytes correlates with increased resistance 
to L. major infection (26).
Interestingly, monocytes are crucial to control the re-infec-
tion of resistant mice with L. major, as they clear the parasites 
through the production of ROS and RNS following activa-
tion by resident memory CD4+ T cells (27, 28). However, 
this phenotype is parasite species specific, as shown fol-
lowing infection with L. amazonensis, where the recruitment 
of inflammatory monocytes was associated with increased 
parasite burden and pathology (29). Similarly, infection of 
human monocytes by different Leishmania species alters 
their adherence to connective tissues (30) and could favor 
dissemination of the infection.
The paradoxical role of pattern recognition receptors
A common characteristic of the different innate immune cells 
is the expression of pattern recognition receptors (PRRs), 
capable of recognizing pathogen-associated molecular pat-
terns (PAMPs). These latter are broadly conserved motifs cov-
ering bacterial endotoxins, lipopeptides and peptidoglycans, 
together with single-stranded (ss) and double-stranded (ds) 
nucleic acids. These PAMPs are recognized via Toll-like recep-
tors (TLRs), cytosolic DNA sensors (CDSs), NOD-like receptors 
(NLRs), RIG-I-like receptors (RLRs) and C-type lectin recep-
tors (CLRs). Because of the numerous ligands expressed by the 
parasite (31, 32), the most studied PRRs are TLRs, which play 
different and often species-specific roles during Leishmania 
infection, adding complexity and diversity to their role in leish-
maniasis but possibly explaining different clinical outcomes 
ranging from clearance to exacerbated pathology (see Fig. 2).
For example, TLR2 promotes the clearance of L.  major, 
L. aethiopica or L. mexicana infection by promoting NO
.
 and 
ROS production, therefore favoring the development of a pro-
tective immune response in mice (33–35). However, TLR2 
stimulation has also been shown to promote the persistence 
of L. braziliensis and L. amazonensis infection by inducing 
the expression of SOD1 through a PKR–IFN-β axis (36). These 
contradictory roles allegedly depend either on the thickness 
of the LPG coat, which vary considerably between parasite 
species or on other molecules still to be identified.
One report suggests that TLR3 is required for the phago-
cytosis of L.  donovani and the subsequent production 
of parasitotoxic NO
.
 and TNF-α by macrophages, thus 
Fig. 2. TLRs’ influence on the outcome of Leishmania infection. Several TLRs are stimulated during Leishmania infection and can have opposite 
consequences on the outcome of the infection depending on parasite species and timing of stimulation. During L. major infection, TLR2 acti-
vation increases the production of ROS and RNS, thus favoring parasite clearance, whereas in L. braziliensis infection it promotes the expres-
sion of SOD, leading to parasite persistence. TLR4 stimulation post-infection promotes TNF-α and NO
.
 production, increasing parasite killing, 
whereas stimulation prior to infection increases IL-10 production, favoring parasite persistence. TLR3 stimulation increases host resistance to 
L. donovani infection, by promoting TNF-α and NO
.
 production, whereas it promotes L. guyanensis virulence, by provoking a hyper-inflamma-
tory response and the dissemination of parasites. TLR9 is the only TLR member which was solely associated with host protection, as it promotes 
IL-12 and IFN-γ production by dendritic cells, thus favoring the development of a protective Th1 immune response.
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promoting parasite clearance despite the source of the lig-
and being unknown (37). In contrast, TLR3 stimulation was 
shown to induce a hyper-inflammatory response associ-
ated with increased symptoms and parasite burden during 
infection with L. guyanensis (38). This exacerbated pheno-
type is associated with the presence of an endosymbiotic 
virus offering its dsRNA genome to induce TLR3-dependent 
hyper-inflammation, suggesting that TLR3 activation by viral 
dsRNA genomes present in co-infection could exacerbate 
Leishmania-dependent pathology.
TLR4 also shows a dual role, depending on the time of 
stimulation. Protective TNF-α and NO
.
 production is observed 
when TLR4 is stimulated at the same time or after Leishmania 
infection (39, 40), whereas stimulation prior to infection was 
associated with increased IL-10 production and parasite per-
sistence (41).
Thus far, only TLR9 has been systematically associated 
with resistance to various Leishmania species infections, 
possibly by stimulating IL-12 production by plasmacytoid 
dendritic cells, which in turn induces IFN-γ production by NK 
cells (42–46). IFN-γ then acts on infected macrophages and 
induces the production of parasitotoxic nitrites.
In conclusion, taken together, information gathered recently 
on the role of TLRs suggests that they can play opposite roles 
in Leishmania infections, depending on the infecting species 
and possibly on additional ligands of bacterial or viral origins 
acting before, during or after the infection.
While currently there is no evidence of an involvement of other 
TLRs, RLRs and CDSs in Leishmania infection, the studies on 
NLRs and CLRs are still rare and present controversial results. 
In fact, NLRP3 activation and IL-1β production were shown 
to protect the host against L. donovani, L. amazonensis and 
L.  braziliensis, via induction of parasitotoxic oxidative stress 
(47). Interestingly, L. donovani promotes macrophage expres-
sion of A20 (48) which inhibits NLRP3 inflammasome activa-
tion (49) and the production of IL-1β (see Fig. 1). On the other 
hand, NLRP3 activation is detrimental in mouse infection with a 
unique L. major strain isolated from a chronic CL patient, as it 
promoted the development of chronic infection by increasing 
neutrophil recruitment at the site of infection and inducing the 
inflammasome and the production of IL-1β (50). One should be, 
however, careful in the interpretation of several studies implying 
a role for the inflammasome since, in several instances, inflam-
masome activation was obtained by lipopolysaccharides (LPS) 
stimulation concomitant with Leishmania infection.
Regarding CLRs, Dectin-1 and mannose receptor stimula-
tion were shown to promote macrophage microbicidal oxida-
tive stress production, favoring the clearance of L. infantum 
infection (51). In contrast, SIGNR3 was shown to promote 
L. infantum infection, by inhibiting IL-1β, whereas Mincle was 
shown to promote the infection of L.  major, by dampening 
dendritic cell priming (51, 52). Defining the molecular path-
ways downstream of the CLRs will be challenging but could 
help to further define their relevance.
Adaptive immune responses to Leishmania
The early phase after Leishmania infection is crucial to deter-
mine the outcome of the disease. In fact, once the parasite 
is phagocytized, innate immune cells react by producing 
cytokines that shape the development of adaptive immu-
nity, thus generating either a protective or detrimental type 
of response. Interestingly, despite being indispensable for 
the complete clearance of the infection and to establish a 
long-lasting memory response conferring protection against 
re-infection, adaptive immune cells have also been shown to 
participate in the pathogenesis of leishmaniasis, causing tis-
sue destruction and inducing disease relapse.
CD4 T cells
Interestingly, the murine model of L. major infection was origi-
nally used to define Th1/Th2 T-cell polarization. In fact, Th1 
response, characterized by the production of IFN-γ and TNF-α 
which induce the activation of the macrophage oxidative stress 
machinery, induces host resistance, whereas Th2  response, 
characterized by IL-4 and IL-13 production, leads to a sus-
ceptible phenotype, unable to control Leishmania infection. 
However, in the last years, it became clear that this correla-
tion is less strict in humans, and a more complex scenario has 
emerged also in the mouse model. In fact, DCL patients often 
show high levels of TNF-α in their lesions, suggesting that a too 
robust Th1 response and the consequent hyper-inflammatory 
state can favor the development of metastatic infection (53).
Moreover, other subsets of Th cells have been implicated 
in leishmaniasis outcome, such as the IL-17-producing Th17 
T cells, which have a controversial, species-specific role. 
Often involved in autoimmune disorders, Th17 T cells have 
been associated with healing in L.  infantum and L.  brazil-
iensis infection (54, 55), whereas they worsen the outcome 
of L.  major- and L.  guyanensis-induced leishmaniasis (56, 
57). Interestingly, in this latter case, IL-17 is associated with 
parasite dissemination and the metastatic infectious lesion 
formation in the absence of IFN-γ, both in humans and mice 
and is correlated with the presence of a viral endosymbiont. 
Finally, IL-10-producing Treg cells have been associated with 
parasite latency, treatment resistance and disease relapse in 
Leishmania infection, both in mice and in humans (58–61).
CD8 T cells
The role of CD8 T cells during Leishmania infection seems to 
depend on the form of leishmaniasis, and ranges from pro-
tective to disease exacerbating (62). In the murine model of 
CL induced by L. major, CD8 T cells are essential to control 
low-dose infection, whereas they are non-essential after high-
dose inoculation (63). In humans, higher numbers of CTLs 
have been observed during the acute and healing phase of 
L. major infection (64–66), allegedly promoting parasite clear-
ance through the higher production of IFN-γ. CD8 T cells 
have a protective role also against VL caused by L. donovani 
and L. infantum, both in the murine model and in humans, as 
CTLs were shown to be essential to the proper formation of 
granulomas. Further, CD8 T cells were associated with resist-
ance to L. infantum re-infection, implying a potential use for 
vaccine development.
Contrarily, higher numbers of IL-10-producing CD8 T cells 
have been observed in DCL and post-kala-azar dermal leish-
maniasis (PKDL) patients (67–69), suggesting their involve-
ment in the dissemination of the disease. Similarly, high 
numbers of granzyme-positive and IL-10-refractory CTLs 
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were associated with tissue destruction and disease progres-
sion in MCL patients (70, 71). Moreover, in the murine model, 
CTLs have been recently associated with increased severity 
and infectious metastasis development during L. braziliensis 
infection (72), and NKG2D+ CD8 T cells have been shown to 
increase the severity of L. major infection following LCMV co-
infection (25, 73).
B cells
B cells are thought to play a negligible role in the pathol-
ogy of leishmaniasis as Leishmania are obligate intracel-
lular parasites. However, a few studies have reported a 
disease exacerbatory role of B cells during L. donovani and 
L.  amazonensis infection (74, 75). In fact, IgM transmem-
brane domain deficient (µMT) mice—which lack mature B 
cells—clear L. donovani infection faster than wild-type (WT) 
mice do, because of enhanced granuloma formation and 
an increased Th1 immune response (74, 76). Nevertheless, 
µMT mice show more severe liver necrosis compared with 
WT mice, because of increased recruitment of neutrophils. 
Similarly, B-cell-deficient mice develop delayed and less 
severe lesions following L.  amazonensis infection (75). In 
contrast, thus far, B cells play no role during L. guyanensis 
infection (77).
Leishmania and co-infection
Differently from the highly sterilized animal models used in re-
search, the human body is constantly in contact with a multi-
tude of microorganisms, which shape the immune response. 
In fact, commensal bacteria modulate L.  major infection, 
as germ-free mice developed a higher parasite burden but 
reduced lesions, through an IL-17-dependent mechanism 
(78), whereas the disruption of the microbiota skin flora exac-
erbates inflammation and lesion development during L. major 
infection (79).
The most intriguing pathogen-Leishmania co-infection is the 
presence of Leishmania RNA virus (LRV) within certain spe-
cies of Leishmania parasites, which was recently described 
to modulate the severity of CL induced by L.  guyanensis 
and L. braziliensis (5, 38). In fact, LRV has been associated 
with the development of DCL, as viral dsRNA recognition by 
TLR3 improves infected macrophage survival by phosphor-
ylation of the pro-survival kinase Akt (77) and is the driving 
force in the dissemination of the infection (57). The pres-
ence of a second species of LRV within L. major and more 
recently in L.  aethiopica, another species known to cause 
DCL, suggests an even greater role of LRV in the determin-
ation of Leishmania infection (80). Moreover, the pathology-
increasing effect of LRV completely relies on production of 
type I interferons, implying that other viral co-infections could 
have the same effect (81).
Of great interest are also the reports of sand fly bearing 
both Leishmania parasites and different Phleboviruses, which 
could thus be transmitted together in a simultaneous co-
infection (82–84). Interestingly, co-infection with the Toscana 
phlebovirus increases both parasite burden and lesion size in 
a murine model of L. guyanensis infection (81). Interestingly, 
the presence of Narna-like virus 1—a virus infecting 
Leptomonas seymouri (protozoan parasites also transmitted 
by sand flies)—has recently been reported in L.  donovani 
isolates from India, underscoring the existence of triple co-
infection and suggesting its involvement in the development 
of PKDL (85).
Currently, HIV is still the most studied co-infecting pathogen 
as it worsens both VL and CL, inducing the development of 
atypical symptoms and increasing treatment resistance and 
disease relapses (86–88). In fact, HIV infection decreases 
CD4 T-cell numbers, favors a Th2 immune response and 
impairs macrophages’ functions, thus promoting parasite 
persistence and disease development (89–91). Interestingly, 
mice co-infected with LCMV, both before or after L. major in-
fection, develop bigger leishmanial lesions, through a mech-
anism involving the increased inflammation generated by 
bystander CD8 T-cell activation (25, 73). Moreover, LCMV 
co-infection increases lesion size and parasite burden, and 
promotes parasite dissemination and disease relapse of 
L.  guyanensis-induced leishmaniasis (81). In this second 
case, the mechanism completely relies on production of type 
I  interferons and is associated with the inhibition of macro-
phage responsiveness to IFN-γ.
Implications for treatment and vaccine development
The current leishmaniasis treatment strategy focuses solely 
on parasitotoxic drugs, neglecting the importance of the host 
immune response. As leishmaniasis is an immune-mediated 
disease, immunotherapy could be crucial for the develop-
ment of new treatments or to improve the efficacy of the cur-
rent ones. In particular, because of the central role of TLRs 
in the initiation of the anti-leishmanial immune response, the 
use of TLR agonists or antagonists could help to improve the 
efficacy of current drugs. For instance, combination treatment 
with the synthetic bacterial lipopeptide Pam3Cys (a TLR2 
ligand) was shown to improve the efficacy of miltefosine in 
a murine model of VL, by promoting a Th1 immune response 
and ROS and RNS production (92). Further, TLR9 stimulation 
with D-type CpG reduced lesion severity and parasite burden 
in Leishmania-infected rhesus macaques (93).
Interestingly, D-type CpG treatment protected also simian 
immunodeficiency virus (SIV)-infected rhesus macaques from 
Leishmania infection, suggesting its possible application in 
Leishmania–HIV co-infected human patients. Moreover, the 
use of a topical formulation of Imiquimod (a TLR7 ligand that 
induces a potent pro-inflammatory response) in combin-
ation with antimony was shown to reduce the healing time 
and improve wound repair in Peruvian CL patients (94), set-
ting the stage for the simultaneous use of TLRs agonists and 
anti-Leishmania drugs as CL therapeutics. Paradoxically, a 
completely opposite strategy—the use of pentoxifylline (a 
TNF-α inhibitor used to treat autoimmune disorders) in com-
bination with antimony—improved healing and reduced the 
relapse rate in MCL patients (95). However, the use of TNF-α 
blockers was also associated with disease re-activation in VL 
patients, and thus should be carefully monitored as a thera-
peutic approach (96).
The development of a leishmanial vaccine remains a major 
challenge. Despite the efforts and different strategies tested, 
ranging from leishmanization to recombinant or DNA vac-
cines, there is still no effective vaccine, with the possible 
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exception of Leishmune® used for dogs. Also in this case, 
the central role of TLR stimulation in the determination of the 
immune response makes TLRs an important candidate not 
only for immunotherapy, but also for vaccine development. 
For instance, TLR4 and TLR9 ligands have been used as 
adjuvants in vaccine formulations, showing promising results 
in the murine model. In fact, the TLR4 agonist ONO-4007 
was shown to boost the efficacy of L. amazonensis antigens, 
inducing protection in BALB/c mice, by promoting the pro-
duction of IL-12 and IFN-γ (97).
Furthermore, the TLR9 agonist CpG was used in many vac-
cine formulations and was shown to improve vaccine efficacy 
by promoting IL-12 production, whereas the combination 
between TLR4 and TLR9 agonists increased their adjuvant 
potency, thus showing a synergizing effect between the two 
TLRs (98). Interestingly, mice immunized with a recombinant 
LRV capsid in combination with CpG are protected against 
the increased pathology of LRV-bearing L.  guyanensis in-
fection (99). Despite not conferring complete protection, 
LRV-based vaccination could be the first pre-emptive agent 
against disseminated leishmaniasis.
Conclusions
Here, we summarized some of the recent knowledge on 
the host immune response to Leishmania and the parasite 
immune evasion strategies. Several aspects of the anti-
leishmanial immune response have been disclosed in the 
last 30 years. We now understand many more facets of the 
immune response to Leishmania than the oversimplified, bi-
dimensional Th1/Th2 dogma. Despite the increasing complex-
ity of anti-leishmanial immunity, a mountain of data underline 
the importance of the balance between the different types of 
immune responses rather than the development of a unique 
and specific response (see Fig. 3).
Moreover, the involvement of bacterial and viral co-
infection (often overlooked in the current murine models 
of infection) in the determination of the outcome of leish-
maniasis highlights the need for new research models, 
better replicating the human immune system and taking 
into account the human microbiome which, on the basis of 
mouse models, is likely to be relevant to control or exacer-
bate Leishmania infection in the case of dysbiosis. Another 
aspect not to underestimate is the cohabitation between 
leishmaniasis and autoimmune disorders. The two diseases 
require completely opposite treatment strategies; thus the 
adjustment of an appropriate therapy could be particularly 
difficult, resulting in a vicious cycle of relapse of one or the 
other disease.
Despite the increased knowledge of the immunology of 
Leishmania infection, the treatment options for leishman-
iasis are still limited and rely on old drugs often adopted 
and repurposed from other diseases, while an effective 
human vaccine has still to be developed. As the outcome 
of Leishmania infection is influenced by multiple factors, 
which could vary extremely between individuals, the use of 
Fig. 3. Protective and pathological anti-Leishmania immune responses. The same cell types have been associated with either host protection 
or disease progression depending on parasite species and host immune-competence. (A) The protective immune response. Monocytes (1) and 
neutrophils (2) are rapidly recruited to the infection site, where they clear Leishmania parasites via ROS production or NET formation, respect-
ively. Subsequently, dendritic cells (DC) migrate to the lymph node (3), where they activate and polarize T cells into different Th populations. The 
development of a predominant Th1 immune response, characterized by production of IFN-γ and TNF-α by CD4
+ and CD8+ T cells (4), activates 
infected macrophages to kill intracellular parasites via production of NO
.
, while a moderate Th2 and Th17 response has been shown to promote 
the control of the parasite and the resolution of the infection (5). The subsequent development of IL-10-producing Treg cells ensures the damp-
ening of the immune response, avoiding the development of chronic inflammation (6). (B) The pathological immune response. The excessive 
recruitment of cytokine-producing monocytes causes hyper-inflammation, which favors parasite persistence (1). Inefficient parasite killing by 
neutrophils hides parasites from macrophages, interfering with the development of the immune response and favoring parasite persistence (2). 
Exaggerated IFN-γ and TNF-α production by CD4+ Th1 cells causes hyper-inflammation resulting in tissue destruction (3), whereas the addition 
of cytotoxic granzymes and perforin by CD8+ T cells promotes parasite dissemination (4). Similarly, a disproportionate Th17 response induces 
tissue destruction and parasite dissemination, resulting in the formation of metastatic lesions (5). In contrast, an excessive Th2 response pro-
motes parasite persistence and the development of chronic infection (6), while high numbers of IL-10-producing Treg cells promote parasite 
persistence and re-activation following the resolution of the disease (7).
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immunotherapy to improve leishmanial treatment should also 
be adapted as a sort of precision medicine. Similarly, the 
parasite species specificity of the immune response required 
to clear Leishmania infection does not facilitate the gener-
ation of a universal vaccine. Thus, despite the recent dis-
covery of an immunodominant antigen conserved in many 
Leishmania species (100), the combination with different 
adjuvants to develop many species-specific formulations 
could be required.
Finally, as the immune responses developed during the 
different types of leishmaniasis are drastically divergent, 
the generation of different outcome-specific anti-leishmanial 
treatments or vaccines might prove more effective than a 
unique solution for leishmaniasis.
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